enGene Therapeutics Inc. (ENGN) stock
ENGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends October 31Also trades as ENGNW
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jul 31, 2026Last filing: 10-Q on Sep 8, 2026Score 3/30
$1.85+0.13 (+7.56%)
Close on Nov 18, 2026Market cap $123.98MP/E –Yield 0.00%
enGene Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
enGene Therapeutics's R&D Expenses for the twelve months ending Jul 31, 2026 was $96.26M, up 30.0% year over year. For fiscal 2025 it was $94.48M, up 146.6% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $94.48M | +146.6% |
| FY2024 | Oct 31, 2024 | $38.32M | +132.8% |
| FY2023 | Oct 31, 2023 | $16.46M | +6.4% |
| FY2022 | Oct 31, 2022 | $15.47M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jul 31, 2026 | $20.09M | -11.0% |
| Q2 FY2026CQ1 2026 | Apr 30, 2026 | $22.20M | +9.8% |
| Q1 FY2026CQ4 2025 | Jan 31, 2026 | $22.26M | +11.4% |
| Q4 FY2025CQ3 2025 | Oct 31, 2025 | $31.72M | +181.4% |
| Q3 FY2025CQ2 2025 | Jul 31, 2025 | $22.58M | +95.5% |
| Q2 FY2025CQ1 2025 | Apr 30, 2025 | $20.21M | +105.1% |
| Q1 FY2025CQ4 2024 | Jan 31, 2025 | $19.97M | +254.3% |
| Q4 FY2024CQ3 2024 | Oct 31, 2024 | $11.27M | +98.8% |
| Q3 FY2024CQ2 2024 | Jul 31, 2024 | $11.55M | +196.1% |
| Q2 FY2024CQ1 2024 | Apr 30, 2024 | $9.86M | +206.5% |
| Q1 FY2024CQ4 2023 | Jan 31, 2024 | $5.64M | +53.6% |
| Q4 FY2023CQ3 2023 | Oct 31, 2023 | $5.67M | – |
| Q3 FY2023CQ2 2023 | Jul 31, 2023 | $3.90M | – |
| Q2 FY2023CQ1 2023 | Apr 30, 2023 | $3.22M | – |
| Q1 FY2023CQ4 2022 | Jan 31, 2023 | $3.67M | – |
See a number that looks wrong?